Shares of redcare Pharmacy are sliding toward a 52-week low, as investor concerns over operational challenges outweigh the company’s reaffirmed revenue projections. the European online pharmacy, which delivers over 100,000 parcels daily [[2]], has seen its stock price decline despite the recent appointment of a new Chief Financial Officer. the coming week is critical for the stock, currently trading around €62.25,to defend the key €60 support level and avoid further declines.
Redcare Pharmacy shares are nearing a year-low as investors weigh operational risks more heavily than confirmed revenue growth. Defending the €60 mark will be critical for the stock.
Redcare Pharmacy is facing continued turbulence on the stock exchange. Despite reaffirming its annual forecast and a change in its Chief Financial Officer, the company’s shares have largely trended downward for months. Currently, the stock is trading dangerously close to a key support level, both psychologically and technically, increasing investor anxiety.
Discrepancy Between Outlook and Share Price
A widening gap exists between the company’s operational communications and its stock performance. Management recently reiterated its goals for fiscal year 2025 and projected continued revenue growth in November, but the capital market has not responded positively. The appointment of Hendrik Krampe as the new CFO, effective December 1, 2025, has also failed to provide a boost.
Market observers interpret the ongoing weakness as a sign that investors are currently prioritizing risk assessment over simple revenue growth. Focus is centered on margin stabilization and uncertainties within the regulated European e-prescription market. Rather than anticipating a recovery, the market appears to be pricing in continued operational challenges.
Technical Analysis: Bears in Control
From a technical perspective, the downtrend remains intact and is driving trading activity. With a closing price of €62.25 on Friday, the stock is dangerously approaching its 52-week low of €60.35. This area around the €60 mark serves as a last major line of defense. A sustained breach of this zone could trigger technically-driven selling and further downward pressure on the price.
A significant difference remains between the expectations of many analysts and the reality in the market. While some experts are calling for price targets above €100, the more than 52 percent loss in value since the beginning of the year reflects deep investor skepticism. Recent attempts at recovery have consistently stalled in the €64 to €65 range.
The coming trading week will be critical in defending the €60 level. As no company-specific news was released over the weekend, the weak momentum from Friday is expected to influence the start of trading on Monday. As long as a clear bottom is not established, the risk of further declines remains acute.
Redcare Pharmacy share: Buy or sell?! A new Redcare Pharmacy analysis from December 7th provides the answer:
The latest Redcare Pharmacy figures speak a clear language: urgent action is needed for Redcare Pharmacy shareholders. Is an entry worthwhile or should you rather sell? In the current free analysis from December 7th you will learn what to do now.
Redcare Pharmacy: Buy or sell? Read more here…
